Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 28 · below the Ichimoku cloud · RSI 37 · MACD above its signal · 9% above its 52-week low
None of the 29 investors followed here reported a position in DRUG in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DRUG trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Cheung (Ryan)Senior Officer of Issuer | Acquisition in the public market at price 49.26 per share. | 100 | $4.93K |
| Sep 29, 2026 | Cheung (Ryan)Senior Officer of Issuer | Acquisition in the public market at price 50.27 per share. | 100 | $5.03K |
| Jun 11, 2026 | Mcdonald (Ian)Director of Issuer | Acquisition in the public market at price 61.08 per share. | 1.6K | $99.26K |
| Jun 2, 2026 | Bottler (Nils Christian)Director of Issuer | Exercise of options at price 1.32 per share. | 5K | $6.62K |
| Jun 2, 2026 | Bottler (Nils Christian)Director of Issuer | Exercise of options at price 1.19 per share. | 2.5K | $2.97K |
| May 31, 2026 | Bottler (Nils Christian)Director of Issuer | Disposition in the public market at price 85.17 per share. | 5K | $425.85K |
| May 27, 2026 | Vasilkevich (Alex)Senior Officer of Issuer | Exercise of options at price 3.80 per share. | 4.5K | $17.11K |
| May 27, 2026 | Vasilkevich (Alex)Senior Officer of Issuer | Exercise of options at price 1.20 per share. | 5K | $5.99K |
| May 27, 2026 | Vasilkevich (Alex)Senior Officer of Issuer | Exercise of options at price 1.34 per share. | 35K | $47.01K |
| Apr 29, 2026 | Vasilkevich (Alex)Senior Officer of Issuer | Disposition in the public market at price 89.66 per share. | 500 | $44.83K |
| Apr 29, 2026 | Vasilkevich (Alex)Senior Officer of Issuer | Disposition in the public market at price 89.12 per share. | 2K | $178.23K |
| Apr 27, 2026 | Cormorant Asset Management ,L.P10% Security Holder of Issuer | Disposition in the public market at price 89.50 per share. | 109.3K | $9.79M |
| Feb 23, 2026 | Fryzuk (Jeremy)Director of Issuer | Exercise of options at price 1.34 per share. | 10K | $13.43K |
| Feb 23, 2026 | Fryzuk (Jeremy)Director of Issuer | Exercise of options at price 1.20 per share. | 7.5K | $9.03K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.4 | 7.8 | -12.9 | 20.5 | 0.1 | -20.3 | 4.4 | -2.1 | -30.5 | 1.8 | −35.0% | ||
| 2025 | -5.6 | 9.5 | -3.1 | -14.9 | -15.5 | 0.6 | 29.3 | 15.1 | 56.0 | -9.7 | 27.9 | 11.5 | +116.7% |
| 2024 | 51.0 | -16.7 | -33.3 | -19.6 | 25.4 | -10.3 | 6.9 | -8.6 | 10.4 | 3900.0 | -6.0 | -18.1 | +2418.9% |
| 2023 | -2.8 | -19.9 | -23.6 | 43.0 | -0.3 | -9.1 | 46.0 | -48.3 | -25.6 | -15.6 | -0.7 | 6.7 | −61.4% |
| 2022 | -23.3 | -14.0 | -27.4 | -38.4 | 17.6 | -27.3 | 24.4 | 93.0 | -35.9 | -19.5 | 10.1 | -32.1 | −76.7% |
| 2021 | -15.8 | 3.5 | -1.4 | 2.1 | 12.9 | 34.6 | -0.3 | -41.4 | -24.0 | −40.8% |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Buy / hold / sell counts